General Prognostics Inc., a Boston, MA-based predictive hearth monitoring startup, received an investment from NEC X.
The amount of the deal was not disclosed.
The investment in GPx is part of NEC X’s broader strategy to support healthcare innovation. It also coincided with GPx joining the Elev X! Boost program, an individually venture program for startups that are ready to scale. The program offers a blend of capital, strategic partnerships, and integrations with NEC X’s tech ecosystem to propel startups to global success.
GPx develops an implant-free device that monitors heart failure changes without invasive procedures. It is dedicated to transforming the standard of care of chronic diseases and enabling patients to better understand their condition, much like the continuous glucose monitor has transformed diabetes care.
Through Elev X! Boost, GPx will refine the accuracy of its debut product, CardioID, an implant and needle-free remote blood monitoring solution for heart failure patients, while growing revenue, expanding into new markets and securing additional funding. The system, developed by GPx, extracts biomarkers from wearable devices, such as heart rate, heart rate variability, step count, and voice data, and employs machine learning to develop predictive models that surpass the accuracy of traditional implant-based monitoring solutions.
